医学
重症监护医学
指南
呼吸窘迫
临床实习
急性呼吸窘迫
儿科
家庭医学
肺
外科
内科学
病理
作者
Nida Qadir,Sarina K. Sahetya,Laveena Munshi,Charlotte Summers,Darryl Abrams,Jeremy R. Beitler,Giacomo Bellani,Roy G. Brower,Lisa Burry,Jen‐Ting Chen,Carol Hodgson,Catherine L. Hough,François Lamontagne,Anica C. Law,Laurent Papazian,Tài Pham,Eileen Rubin,Matthew Siuba,Irene Telías,Setu Patolia
标识
DOI:10.1164/rccm.202311-2011st
摘要
Background: This document updates previously published Clinical Practice Guidelines for the management of patients with acute respiratory distress syndrome (ARDS), incorporating new evidence addressing the use of corticosteroids, venovenous extracorporeal membrane oxygenation, neuromuscular blocking agents, and positive end-expiratory pressure (PEEP). Methods: We summarized evidence addressing four "PICO questions" (patient, intervention, comparison, and outcome). A multidisciplinary panel with expertise in ARDS used the Grading of Recommendations, Assessment, Development, and Evaluation framework to develop clinical recommendations. Results: We suggest the use of: 1) corticosteroids for patients with ARDS (conditional recommendation, moderate certainty of evidence), 2) venovenous extracorporeal membrane oxygenation in selected patients with severe ARDS (conditional recommendation, low certainty of evidence), 3) neuromuscular blockers in patients with early severe ARDS (conditional recommendation, low certainty of evidence), and 4) higher PEEP without lung recruitment maneuvers as opposed to lower PEEP in patients with moderate to severe ARDS (conditional recommendation, low to moderate certainty), and 5) we recommend against using prolonged lung recruitment maneuvers in patients with moderate to severe ARDS (strong recommendation, moderate certainty). Conclusions: We provide updated evidence-based recommendations for the management of ARDS. Individual patient and illness characteristics should be factored into clinical decision making and implementation of these recommendations while additional evidence is generated from much-needed clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI